The National Agency for the Control of AIDS has clarified guidelines on the new HIV prevention injection. The agency stated that Lenacapavir is not recommended for pregnant women.
According to Director-General Temitope Ilori, global studies confirm the drug’s safety profile. However, experts still lack sufficient evidence regarding its effects during pregnancy. Therefore, authorities advise caution for this specific group.
She emphasised that Lenacapavir serves as a preventive option, not a treatment method. In addition, she warned that it does not protect against other infections. These include sexually transmitted infections and diseases like Hepatitis. Consequently, individuals must continue using comprehensive preventive measures.
Meanwhile, the National AIDS and STDs Control Programme is working to expand access nationwide. National Coordinator Adebobola Bashorun explained that funding efforts are ongoing. These efforts aim to increase doses and reach high-risk populations.
Furthermore, health officials confirmed that Lenacapavir will complement existing HIV prevention strategies. For instance, individuals can still rely on oral PrEP for protection. Authorities will integrate the injection through updated national health policies.
On safety, experts reported mostly mild side effects, including injection-site pain. They continue monitoring patients to ensure long-term safety outcomes.
Additionally, the Federal Ministry of Health and Social Welfare highlighted international support for the rollout. The Global Fund currently supports access to the drug.
Overall, Lenacapavir offers a promising advancement in HIV prevention. However, experts stress the need for funding, accessibility, and sustainable healthcare strategies.
